Where does Immunome's cash flow data come from?

Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immunome IMNM Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$212.39M+27.5%	-$292.96M-174%	-$106.81M-189%	-$36.9M-49.3%
Depreciation and amortization	$2.47M+57.4%	$1.57M+243%	$457K+8.3%	$422K-44.1%
Stock-based compensation	$25.69M+63.1%	$15.75M+153%	$6.22M+16.7%	$5.33M+54.6%
Gain (loss) on sale of assets	-$946K—	——	——	——
Change in accounts payable	——	——	-$608K+10.2%	-$677K—
Change in other assets	——	——	$4.14M+179%	-$5.24M-222%
Change in deferred revenue	——	-$9.04M—	——	——
Non-cash operating lease expense	$489K-8.6%	$535K+97.4%	$271K+29.7%	$209K—
Change in operating lease liabilities	-$166K—	——	——	——
Net cash from operating activities	-$190.92M-72.3%	-$110.79M—	——	-$28.69M-57.4%
Capital expenditures	$9.69M+35.0%	$7.17M+763%	$831K+235%	$248K+214%
Acquisitions, net of cash acquired	——	——	$9.28M—	——
Proceeds from maturities/sales of investments	$200M—	——	——	——
Acquired in-process research and development	——	$46.34M—	——	——
Net cash from investing activities	$64.8M—	——	-$30.48M-12,192%	-$248K-214%
Proceeds from issuance of common stock	$45.9M+129%	$20M—	——	——
Net cash from financing activities	$640.41M+166%	$240.53M+107%	$116.41M—	——
Net increase (decrease) in cash	——	——	$84.36M+392%	-$28.91M—
Accretion (Amortization) of Discounts and Premiums, Investments	$2.84M-2.1%	$2.9M—	——	——
Charge For Purchase Of In Process Research And Development Assets Including Upon Achievement Of Milestones	$10M-93.4%	$152.34M—	——	——
Increase Decrease In Accrued Expenses And Other Current Liabilities	——	$13.55M+2,107%	$614K—	——
Operating lease liabilities	-$166K—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$4.14M+179%	-$5.24M-222%
Operating lease right-of-use asset amortization	$489K-8.6%	$535K+97.4%	$271K+29.7%	$209K—
Payments to Acquire in Process Research and Development	——	$46.34M—	——	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$200M—	——	——	——
Payment Of Offering Costs	$39.46M+159%	$15.23M—	——	——
Proceeds From Public Offering	——	——	——	——
Proceeds From Warrant Exercises	——	——	——	——
Accrued payables for capital expenditures	——	——	$372K—	——
Increase Decrease In Contract With Customer Liability	——	-$9.04M—	——	——
Increase Decrease In Operating Lease Liability	-$166K—	——	——	——
Accrued payables for stock repurchases, including applicable excise tax	——	——	——	——
Offering Cost Included In Accounts Payable Accrued Expenses And Other Current Liabilities	——	$0—	——	——
Purchases Of In Process Research And Development Assets Including Payments Owed Upon Achievement Of Development Milestones In Accounts Payable And Accrued Expenses	——	$6.25M—	——	——
Leased assets obtained in exchange for operating lease liabilities	——	$1.19M-10.3%	$1.33M—	——
Free cash flow	-$200.6M-70.1%	-$117.97M—	——	-$28.94M-58.1%
Free cash flow	-$200.6M-70.1%	-$117.97M—	——	-$28.94M-58.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Immunome's cash flow data come from?: Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.